Revotek
A pioneering regenerative medicine company specializing in biological additive manufacturing, specifically the world's first 3D bioprinted stem cell vascular grafts (REVOVAS) and proprietary 'Biosynsphere' bio-ink technology.
- CEO / Founder
- Professor Y. James Kang
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $41.4M
- Latest Round
- Corporate Round
- Key Investors
- Sichuan Languang Development (600466.SH), Chinese State 863 Program (Grants)
Technology & Products
Key Products
["REVOVAS®: 3D bioprinted stem cell vascular transplant system","Biosynsphere® (Biological Bricks): Proprietary stem cell-based bio-ink","3D Bio-vascular Printer: World's first specialized vascular bioprinting hardware","Medical Imaging Cloud Platform: AI-driven modeling system for personalized organ/tissue design","Bio-active Post-printing Treatment System"]
Technological Advantage
Combines stem cell biology with additive manufacturing and AI cloud modeling to achieve 'organ regeneration' rather than mere mechanical substitution; features a 1700+ day successful follow-up in non-human primate trials, the longest in the industry.
Differentiation
Value Proposition
Enables the creation of bio-active, personalized vascular grafts that integrate seamlessly with host tissue (endothelialization), eliminating the need for long-term anticoagulant medication and overcoming the limitations of synthetic or cadaveric grafts.
How They Differentiate
Revotek utilizes a proprietary 'spatial rotating bioprinting platform' and 'Biosynsphere' (stem cell biological bricks) to create living, scaffold-free vascular grafts that integrate and endothelialise within the host, unlike the needle-array (Kenzan) methods or synthetic scaffold approaches used by competitors.
Market & Competition
Target Customers
Patients with end-stage vascular diseases (e.g., Peripheral Arterial Disease - PAD), cardiovascular surgeons, and healthcare institutions requiring regenerative tissue solutions.
Industry Verticals
["Regenerative Medicine","Cardiovascular Healthcare","Organ Manufacturing","Pharmaceutical Drug Screening","Biotechnology Research"]
Competitors
Regenovo Biotechnology (Hangzhou); Cyfuse Biomedical (Japan); Organovo (USA)
Growth & Milestones
Growth Metrics
Transitioned from R&D to clinical research stage with National Health Commission (NHC) approval in 2022; holds over 50 core patents in cell printing.
Major Milestones
["2015: Launched the world’s first 3D biological vascular printer","2016: Achieved world's first successful implantation of 3D bioprinted vessels in rhesus monkeys","2019: Documented survival of implanted vessels reaching over 1000 days in animal models","2022: Received National Health Commission approval for First-in-Human (FIH) clinical trials","2024: Featured on CCTV-4 for leadership in clinical regenerative medicine"]
Notable Customers
West China Hospital of Sichuan University (Strategic Clinical Partner)